Company research
Immunome Inc.
CIK 1472012Updated Sep 24, 2026
SecurityIMNM · NASDAQ · equity
IMNM price & chart
Loading TradingView…
NASDAQ:IMNM on TradingView ↗About the company
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 683,188,000Source | 240,241,000Source | 148,540,000Source | 24,046,000Source |
| Property, Plant and Equipment, NetUSD | 14,636,000Source | 10,113,000Source | 2,073,000Source | 681,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 653,482,000Source | 143,351,000Source | 98,679,000Source | 20,323,000Source |
| Assets, CurrentUSD | 660,777,000Source | 221,339,000Source | 144,703,000Source | 22,649,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,295,000Source | 4,036,000Source | 6,561,000Source | 2,326,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,978,000Source | 4,278,000Source | 1,564,000Source | 284,000Source |
| Other Assets, NoncurrentUSD | 4,587,000Source | 4,411,000Source | 100,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 48,845,000Source | 59,076,000Source | 28,658,000Source | 7,393,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 11,000Source | 6,000Source | 4,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 1,362,496,000Source | 696,872,000Source | 342,663,000Source | 132,653,000Source |
| Retained Earnings (Accumulated Deficit)USD | -728,164,000Source | -515,770,000Source | -222,807,000Source | -116,001,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 57,000Source | 22,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 634,343,000Source | 181,165,000Source | 119,882,000Source | 16,653,000Source |
| Liabilities and EquityUSD | 683,188,000Source | 240,241,000Source | 148,540,000Source | 24,046,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 44,990,000Source | 54,307,000Source | 21,829,000Source | 7,331,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 63,000Source | — | — |
| Accounts Payable, CurrentUSD | 3,339,000Source | 14,189,000Source | 3,311,000Source | 2,400,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,855,000Source | 4,769,000Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | 801,000Source | 1,033,000Source | 378,000Source | — |
| Other Liabilities, NoncurrentUSD | — | — | 1,340,000Source | 62,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -212,394,000Source | -292,963,000Source | -106,806,000Source | -36,896,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,466,000Source | 1,567,000Source | 457,000Source | 422,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 25,690,000Source | 15,748,000Source | 6,223,000Source | 5,332,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -9,164,000Source | 9,526,000Source | -608,000Source | -677,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -190,919,000Source | -110,794,000Source | -7,568,000Source | -28,690,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 60,803,000Source | -85,063,000Source | -30,484,000Source | -248,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 9,685,000Source | 7,173,000Source | 831,000Source | 248,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 640,357,000Source | 240,529,000Source | 116,408,000Source | 32,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 510,241,000Source | 44,672,000Source | 78,356,000Source | -28,906,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 653,692,000Source | 143,451,000Source | 98,779,000Source | 20,423,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 25,690,000Source | 15,748,000Source | 6,223,000Source | 5,332,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -896,000Source | — | — | — |
| General and Administrative ExpenseUSD | 43,768,000Source | 32,955,000Source | 19,657,000Source | 13,629,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -212,394,000Source | -292,963,000Source | -106,806,000Source | -36,896,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -212,394,000Source | -292,963,000Source | -106,806,000Source | -37,518,000Source |
| Operating ExpensesUSD | 231,054,000Source | 314,841,000Source | 123,548,000Source | 36,901,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 5,000Source |
| Proceeds from Issuance of Common StockUSD | 45,897,000Source | 20,000,000Source | 34,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 200,000,000Source | 155,000,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 913,000Source | 2,024,000Source | 371,000Source | 32,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 6,941,000Source | 9,041,000Source | 14,018,000Source | — |
| Operating Income (Loss)USD | -224,113,000Source | -305,800,000Source | -109,530,000Source | -36,901,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 5,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -212,394,000Source | -292,963,000Source | -106,806,000Source | -36,896,000Source |
| Earnings Per Share, BasicUSD per share | -2.43Source | -5Source | -5.38Source | -3.09Source |
| Earnings Per Share, DilutedUSD per share | -2.43Source | -5Source | -5.38Source | -3.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 87,350,956Source | 58,639,441Source | 19,843,651Source | 12,126,573Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 87,350,956Source | 58,639,441Source | 19,843,651Source | 12,126,573Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 43,768,000Source | 32,955,000Source | 19,657,000Source | 13,629,000Source |
| Interest Income (Expense), NetUSD | 11,719,000Source | 12,837,000Source | 2,724,000Source | 5,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -212,394,000Source | -292,963,000Source | -106,806,000Source | -37,518,000Source |
| Operating ExpensesUSD | 231,054,000Source | 314,841,000Source | 123,548,000Source | 36,901,000Source |
| Research and Development ExpenseUSD | 177,286,000Source | 129,542,000Source | 23,089,000Source | 23,272,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | 622,000Source |
Filing attachments
imnm-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 imnm-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update August 11, 2026 • Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors • Detailed Phase 3 RINGSIDE data presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating statistically significant improv…
Read attachment ↗imnm-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 imnm-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Immunome Reports First Quarter 2026 Financial Results and Provides Business Update May 12, 2026 • New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors • Detailed Phase 3 RINGSIDE data selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting • Phase 1 study ongoin…
Read attachment ↗imnm-ex99_1.htm · 8-K · 2026-03-03
EX-99.1 2 imnm-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Immunome Reports Full Year 2025 Financial Results and Provides Business Update Mar. 3, 2026 • New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 • IM-1021 Phase 1 ongoing with initial data expected in 2026 • Three IND submissions for solid tumor-targeted ADC programs planned in 2026 • Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending p…
Read attachment ↗d27244dex991.htm · 8-K · 2025-12-17
EX-99.1 4 d27244dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Immunome Announces Proposed Public Offering of Common Stock December 15, 2025 BOTHELL, Wash. - Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $400 million of shares of its common stock. All of the shares …
Read attachment ↗d27244dex992.htm · 8-K · 2025-12-17
EX-99.2 5 d27244dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Immunome Announces Pricing of Public Offering of Common Stock December 16, 2025 BOTHELL, Wash. - Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Imm…
Read attachment ↗d793961dex991.htm · 8-K · 2025-12-15
EX-99.1 2 d793961dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a m…
Read attachment ↗